CEL-SCI logo

CVM - CEL-SCI News Story

$6.17 0.5  9.4%

Last Trade - 9:10pm

Sector
Healthcare
Size
Small Cap
Market Cap £179.9m
Enterprise Value £159.0m
Revenue £n/a
Position in Universe 4546th / 7405

BRIEF-Cel-Sci gives update on partial clinical hold on phase 3 head and neck cancer study with multikine

Mon 6th March, 2017 1:00pm
March 6 (Reuters) - Cel-sci Corp  CVM.A  
    * Cel-Sci gives update on partial clinical hold on phase 3 
head and neck cancer study with multikine 
    * Cel-Sci - pursuant to partial clinical hold, patients 
currently receiving study treatments can continue to receive 
treatment at discretion of physicians 
    * Cel-Sci - patients already enrolled in multikine drug 
study will continue to be followed 
    * Cel-Sci-To provide updated investigator's brochure, 
procedures for compliance with requirements under 21 cfr 312 
subpart d to address partial clinical hold 
    * Cel-Sci - to provide to FDA list of major protocol 
deviations, which cel-sci believes will "affect study results" 
    * Cel-Sci - to provide FDA a plan to identify major protocol 
deviations across all patients enrolled in phase 3 protocol for  
multikine drug 
 
Source text for Eikon:  ID:nBwb6Twwza  
Further company coverage:  CVM.A  
 
 ((bangalore.newsroom@thomsonreuters.com;))
© Stockopedia 2022, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.